Optimus Pharma Gains First-in-India DCGI Approval for Tapinarof Cream 1% in Dermatology

Optimus Pharma has secured a DCGI approval for Tapinarof cream 1%, becoming the first Indian manufacturer to clear the regulatory pathway for this non-steroidal topical agent, a development that signals the Drugs Controller General of India is actively processing novel mechanism-of-action dermatology formulations at a pace comparable to other major markets.

Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist, a mechanistic class distinct from corticosteroids and calcineurin inhibitors. Its approval in India follows a regulatory trajectory already established in the United States, where the molecule received FDA clearance for plaque psoriasis. For regulatory affairs leads tracking global dossier strategy, the DCGI nod confirms that the Indian submission pathway for novel topical actives is viable without requiring a prior domestic precedent.

For QA directors and plant heads preparing manufacturing documentation, the approval carries immediate process implications. Tapinarof cream formulations require stability and compatibility data specific to the AhR agonist class, and any site supporting commercial supply will need to demonstrate process validation aligned with 21 CFR Part 211 equivalents under Schedule M of the Drugs and Cosmetics Act. Sterility assurance considerations, while less acute for a cream than for a sterile injectable, remain relevant at the fill-finish and packaging stages given the chronic-use patient population.

The approval also positions Optimus Pharma as the reference holder for this molecule within India, a status that carries weight in any future out-licensing or co-marketing discussions with dermatology-focused commercial partners. Regulatory affairs teams at competing manufacturers monitoring the DCGI's approval cadence for non-steroidal topicals should note that this clearance establishes a precedent dossier structure for the AhR agonist class in the Indian jurisdiction.

The next measurable checkpoint is commercial launch readiness, specifically whether Optimus Pharma's manufacturing site holds the GMP certifications required to supply at scale under the newly granted approval.

Source: Media4Growth via Indian Pharma Post, 16 August 2026.